Date	Insider	Type	Value
Mar 31, 2026	Adler Oz	SELL	$39.7K
Mar 31, 2026	Carmel Liron	SELL	$11.6K
Mar 31, 2026	Izraeli Tomer	SELL	$5.9K
Mar 30, 2026	Carmel Liron	SELL	$1.1K
Mar 30, 2026	Izraeli Tomer	SELL	$42.5K

∅

No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.

4 unique insiders with 6 transactions. Net insider value: -$132.6K ($0.00 bought, $132.6K sold).

Insider Transactions

Date	Insider	Title	Type	Shares	Price	Value
Mar 31, 2026	Adler Oz	Director	SELL	3,292	$12.05	$39.7K
Mar 31, 2026	Carmel Liron	Director	SELL	942	$12.36	$11.6K
Mar 31, 2026	Izraeli Tomer	Chief Executive Officer	SELL	500	$11.85	$5.9K
Mar 30, 2026	Carmel Liron	Director	SELL	100	$11.00	$1.1K
Mar 30, 2026	Izraeli Tomer	Chief Executive Officer	SELL	3,900	$10.90	$42.5K
Mar 30, 2026	Turgeman Tidhar	Chief Technology Officer	SELL	2,917	$10.90	$31.8K

10 SEC filing reports analyzed. Sentiment: 0 bullish, 3 bearish, 2 mixed, 5 neutral. Avg impact: 4.3/10.

NEUTRAL 6-K 3/10

Polyrizon announced that the European Patent Office has completed technical preparations for publica

Jun 10, 2026

MIXED 6-K 6/10

Polyrizon Ltd. filed two 6-K reports on June 8, 2026: one announcing it has contracted three U.S. cl

Jun 8, 2026

NEUTRAL 6-K 3/10

Polyrizon Ltd. announced an extension of the exclusivity and negotiation period under its non-bindin

Jun 5, 2026

NEUTRAL 6-K 4/10

Polyrizon announced signing its first Clinical Trial Agreement (CTA) with a U.S.-based clinical site

May 13, 2026

NEUTRAL 6-K 3/10

Polyrizon announced submission of amended claims in a U.S. patent application for its intranasal dru

May 4, 2026

NEUTRAL F-1/A 2/10

Polyrizon Ltd. filed Amendment No. 1 to its F-1 registration statement as an exhibits-only filing to

Apr 30, 2026

MIXED 6-K 5/10

Polyrizon Ltd. (PLRZ) announced the filing of a divisional European patent application for its Trap

Apr 27, 2026

BEARISH 6-K, PRESS-RELEASE 5/10

Polyrizon Ltd. (PLRZ) closed a $3.5 million registered direct offering and concurrent private placem

Apr 8, 2026

BEARISH 424B5 5/10

Polyrizon Ltd. (PLRZ) is conducting a follow-on offering to raise approximately $2.3 million in net

Apr 8, 2026

BEARISH CLUSTER 7/10

Four corporate insiders at Polyrizon Ltd., including the CEO and CTO, sold shares in a coordinated 7

Apr 1, 2026

NEUTRAL 4/10

Polyrizon announced agreements with two additional U.S. clinical sites for its NASARIX (PL-14) clini

Jun 8, 2026

NEUTRAL 3/10

Polyrizon Ltd. announced the filing of its Annual Report on Form 20-F for the fiscal year ended Dece

Mar 25, 2026

NEUTRAL 4/10

Polyrizon Ltd. (PLRZ) announced a non-binding MOU to acquire up to 20% of Colugo Systems Ltd., an Is

Mar 24, 2026

NEUTRAL 4/10

Polyrizon Ltd. announced a strategic agreement with a leading global preclinical CRO to conduct ISO

Mar 17, 2026

NEUTRAL 5/10

Polyrizon Ltd. announced the successful production of a GMP-compliant clinical trial material batch

Mar 10, 2026

Earnings Estimates & Revisions

Period	EPS Avg	EPS Low	EPS High	EPS Growth	30d Rev.	Up/Down	Rev. Avg	Rev. Growth	Analysts
Current Q	$0.00	$0.00	$0.00	—	—	—	$0.0B	—	—
Next Q	$0.00	$0.00	$0.00	—	—	—	$0.0B	—	—
Current FY	$0.00	$0.00	$0.00	—	—	—	$0.0B	—	—
Next FY	$0.00	$0.00	$0.00	—	—	—	$0.0B	—	—

∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

Jun 10, 2026

other

Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology

Raanana, Israel, June 10, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech com

Jun 8, 2026

announcement

Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial

Raanana, Israel, June 08, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech com

May 13, 2026

other

Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial

Raanana, Israel, May 13, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech comp

May 4, 2026

other

Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform

Raanana, Israel, May 04, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech comp

Apr 27, 2026

other

Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform

Raanana, Israel, April 27, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech com

Apr 8, 2026

offering

Polyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private Placements

RAANANA, ISRAEL, April 08, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ) (the “Company”), a pre-clinic

Mar 26, 2026

other

Polyrizon Provides 2025 and Recent Highlights

Company Concluded 2025 with Robust Cash Position, Debt-Free Balance Sheet and Significant Pipeline Achievements <pre>Company Concluded 2025 with Robus

Mar 25, 2026

earnings

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025

Raanana, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechno

Mar 24, 2026

m_and_a

Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility Applications

The Company signed a non-binding MOU with shareholders of Colugo. Colugo’s customer include the Israel Defense Forces, national first res

Mar 17, 2026

announcement

Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program

Raanana, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechno

Mar 10, 2026

fda

Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study

Raanana, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechno